Home

 

 

Latest Discussions

Member Spotlight

Latest Specialty News

  • Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options. We evaluated selinexor, an orally bioavailable, first-in-class inhibitor of the nuclear export protein XPO1, in this phase 1 trial to assess safety and determine a recommended phase 2 dose (RP2D).
  • Submissions for both the photo and the video contests are being accepted now through June 30. Members are encouraged to submit photos from their day to day lives into the annual photo contest as well as submit a video for our Real Life Super Hero Video Contest . To see last year’s video contest winner click here . Don’t forget, everyone is a winner! Participants can earn APHON bucks for each of their submissions. Learn more.
  • The APHON Annual Conference and Exhibit is the premier educational experience for nurses who specialize in pediatric hematology/oncology nursing. This year’s conference in Palm Springs is the perfect opportunity to gain valuable knowledge from experts in the field, network with nurses who experience the same daily challenges, and earn continuing nursing education credit.

How to Login

How to Add a Personal Contact

How To Update Your Profile

How to Post & Reply to a Discussion

How to Post to the Library